Geron Selvein Registers World's First Patent for Uniform Low Molecular Weight PDRN Manufacturing

Specialized pharmaceutical manufacturer Jeronselvain announced on the 31st that it has registered a patent related to technology for producing nucleic acid fragments of uniform size.

According to the patent registered by Jeronselvain, this pertains to technology for manufacturing nucleic acid fragments. This is Jeronselvain's exclusively developed Prism Technology (P-TA), which produces nucleic acid fragments of uniform size and can provide the manufactured nucleic acids for various uses, making it applicable in diverse regenerative therapies.

In particular, PDRN (polydeoxyribonucleotide), a DNA (gene) substance extracted from low-molecular-weight salmon germ cells produced by the nucleic acid fragment manufacturing method, has been proven to have low viscosity, high proliferation rates, and growth factor activation effects.

Fragmented nucleic acids are essential components of cells and are used in pain and regenerative medical treatments such as periodontitis. They are used for wound site treatment and improvement, as well as cell activation. Following medical applications, they can also be used cosmetically for skincare purposes, effectively aiding in whitening, moisturizing, and elasticity enhancement.

Kim Deok-gyu, CEO of Jeronselvain, stated, “Through the nucleic acid fragment manufacturing technology registered in this patent, we confirmed low viscosity that can be industrially applied,” adding, “The lower the viscosity, the higher the permeability, making it easier to administer high doses when applied to the human body, which is expected to be advantageous.”

He continued, “We will further accelerate regenerative medicine and cosmetic raw material development by utilizing this patented technology.”

This content was produced with the assistance of AI translation services.